UBM logo

Ulisse Biomed S.p.A. Stock Price

BIT:UBM Community·€19.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

UBM Share Price Performance

€0.79
-0.01 (-0.75%)
€0.79
-0.01 (-0.75%)
Price €0.79

UBM Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with mediocre balance sheet.

5 Risks
2 Rewards

Ulisse Biomed S.p.A. Key Details

€925.9k

Revenue

€1.7m

Cost of Revenue

-€804.4k

Gross Profit

€4.5m

Other Expenses

-€5.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.22
-86.89%
-572.63%
4.7%
View Full Analysis

About UBM

Founded
2015
Employees
18
CEO
Nicola Basile
WebsiteView website
www.ulissebiomed.com

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases and HPV. In addition, the company’s platforms also comprise NanoHybrid, a platform to detect specific antibodies and protein analytes directly from serum or whole blood; and Aptavir platform to develop and produce synthetic nucleic acid molecules to limit the infectivity of pathogens. Ulisse Biomed S.p.A. was founded in 2015 and is based in Udine, Italy.

Recent UBM News & Updates

Recent updates

No updates